BioBridgeX
Log inCompare quotes
Modality

PROTAC / Targeted Protein Degrader CRO and CDMO vendors

Free for buyersNeutral marketplace
Quick answer

Outsourcing a PROTAC or targeted protein degrader means buying degrader-specific medicinal chemistry, E3 ligase and ternary-complex expertise, degradation and DMPK assays, and CMC for large bifunctional molecules that break the Rule of Five. You need CROs and CDMOs fluent in this modality, not generalists. On BioBridgeX, buyers source and compare vetted suppliers in one place, free for buyers.

PROTAC / Targeted Protein Degrader CRO and CDMO vendors on BioBridgeX

We are qualifying and publishing PROTAC / Targeted Protein Degrader CRO and CDMO vendors now. Tell us what you need and we will match you with vetted vendors, or list your organization to be among the first.

What does it take to develop and manufacture a PROTAC / Targeted Protein Degrader drug?

A PROTAC is a bifunctional molecule: one end binds your target protein, the other recruits an E3 ubiquitin ligase, and a linker holds the two together. The biology you are paying for is event-driven, not occupancy-driven. The degrader pulls the target into a productive ternary complex, tags it for the proteasome, then lets go and does it again. That mechanism is the whole reason the modality exists (it can hit targets small molecules call undruggable), and it is also why a generalist small-molecule CRO will struggle. The design space sits in the linker and the ternary complex, and neither shows up in a standard binding assay.

Discovery work here is its own discipline. You need a CRO that can run linker chemistry at scale, swap E3 ligase handles (CRBN and VHL are the workhorses, but IAP, DCAF15, and newer ligases matter when you want tissue selectivity or want to dodge resistance), and read out degradation directly. That means DC50 and Dmax from Western blot or quantitative proteomics, HiBiT or NanoBRET ternary-complex assays, ubiquitination and proteasome-dependence controls, and a washout experiment to prove catalytic, sub-stoichiometric activity. A supplier who only reports target binding has measured the wrong thing. Watch for the hook effect too, where too much compound forms unproductive binary complexes and degradation falls off at high dose. A team that has not designed around that curve has not really worked in degraders.

The harder, less glamorous half is CMC and DMPK, and it is where specialist degrader CDMOs separate from generalists. PROTACs are big (molecular weights routinely north of 800 to 1,000 Da), greasy, and firmly in beyond-Rule-of-Five space, which punishes solubility, permeability, and oral bioavailability. Synthesis is a long convergent route with an expensive E3 ligand and a linker coupling that has to be clean and reproducible. You want a CDMO that has solved degrader-specific problems: enabling formulations (amorphous solid dispersions, lipid systems) to rescue exposure, analytical methods that resolve regioisomers and linker-related impurities, polymorph and salt screening on a sticky molecule, and GMP scale-up of a route with several chiral and amide-coupling steps. The analytical burden is real because the impurity profile of a bifunctional molecule is more complex than a conventional small molecule of the same dose.

How do you choose a CRO or CDMO for PROTAC / Targeted Protein Degrader?

Fit to the modality beats brand and beats price. The fastest filter is to ask what degraders the team has actually moved forward, not how many small molecules they make a year. A group that has taken at least one PROTAC from linker optimization through a degradation-driven SAR campaign, or a CDMO that has run GMP synthesis of a beyond-Rule-of-Five bifunctional, is in a different league from a competent generalist learning on your program. Run two or three suppliers against the same written scope and compare on the points below.

  • Relevant platform and track record: degrader-specific medicinal chemistry, an E3 ligand and linker toolkit (CRBN, VHL, and ideally beyond), ternary-complex and degradation assays in house (HiBiT, NanoBRET, quantitative proteomics), and named programs they have advanced. Ask whether the scientists you would work with have run degrader SAR, not just heard of it.
  • GxP and analytical capability for this modality: for IND-enabling and clinical supply, GLP bioanalysis and GMP manufacturing that can handle a large, lipophilic molecule. Confirm they can develop stability-indicating methods that resolve linker-related and regioisomeric impurities, run polymorph and salt screening, and build enabling formulations to fix solubility and exposure.
  • Capacity and scale: realistic queue and lead time, plus a credible path from milligram discovery batches to kilogram GMP without re-inventing the route. A long convergent synthesis with a costly E3 ligand makes early route and supply planning matter more than it would for a simple small molecule.
  • Regulatory experience: degraders are still a newer class, so regulators ask sharper questions on impurities, genotoxic risk, and off-target degradation. Favor a supplier that has supported an IND or CTA for a degrader or an unconventional small molecule and can speak to those expectations.
  • IP and confidentiality: linker designs, E3 ligand choices, and the degrader composition are the crown jewels. Settle ownership of compounds, methods, and any platform-derived IP in writing, and have a CDA in place before you disclose target or chemistry.

Frequently asked questions

What makes outsourcing a PROTAC different from a normal small molecule?
The mechanism and the molecule both change what you are buying. A PROTAC works by recruiting an E3 ligase and degrading the target catalytically, so the meaningful readouts are degradation (DC50, Dmax), ternary-complex formation, and a washout that proves the compound acts sub-stoichiometrically, not a binding curve. The molecule itself is large, lipophilic, and beyond Rule of Five, which strains solubility, permeability, oral exposure, and the synthetic route. A generalist CRO can make the compound, but a degrader-experienced team designs the linker, picks the E3 handle, designs around the hook effect, and solves the formulation and analytical problems that come with a bifunctional molecule.
Do I need a specialist degrader CDMO, or can a generalist small-molecule CDMO handle PROTAC manufacturing?
A generalist can run the chemistry, but the failure points in PROTAC CMC are specific and a degrader-experienced CDMO has usually already hit them. Expect a long convergent synthesis built around an expensive E3 ligand and a linker coupling that has to stay clean at scale, an impurity profile (regioisomers, linker-related species) that demands more capable analytical methods, polymorph and salt behavior on a sticky molecule, and formulation work to rescue solubility and oral exposure. If a CDMO has solved those on a prior degrader or a similar beyond-Rule-of-Five molecule, you spend less time and money teaching them on your program.
Which E3 ligases and degradation assays should a PROTAC CRO support?
CRBN (cereblon) and VHL are the standard E3 ligase recruiters and any serious degrader CRO works with both. Beyond those, IAP, DCAF15, and newer ligases come into play when you want tissue selectivity, a different expression profile, or a way around acquired resistance, so ask what handles the team can actually access. On the readout side, you want direct degradation measurement (Western blot or quantitative proteomics for DC50 and Dmax), ternary-complex assays such as HiBiT or NanoBRET, ubiquitination and proteasome-dependence controls, and a washout experiment to confirm catalytic activity. A supplier reporting only target binding has not characterized the degrader.
Why do PROTACs have poor oral bioavailability and how do CRO and CDMO partners address it?
PROTACs are bifunctional, so they carry two binding warheads plus a linker and routinely exceed 800 to 1,000 Da, which puts them well into beyond-Rule-of-Five space. High molecular weight and lipophilicity hurt aqueous solubility and passive permeability, and that shows up as low and variable oral exposure. Capable partners attack it from both ends: medicinal chemistry trims and rigidifies the linker and tunes physicochemical properties during SAR, and CMC builds enabling formulations such as amorphous solid dispersions or lipid-based systems to lift solubility and absorption. Strong DMPK characterization early, including permeability and metabolic stability, keeps the program from optimizing potency on a molecule that will never get into blood.
What is the hook effect and why does it matter when scoping a degrader program?
The hook effect is the dose-response signature unique to bifunctional degraders. At the right concentration the compound forms a productive ternary complex (target plus degrader plus E3 ligase) and degradation peaks. Push the dose too high and the compound saturates each protein separately, forming unproductive binary complexes, so degradation actually falls and the curve hooks downward. It matters because it shapes how you design assays, interpret SAR, and ultimately think about dosing. A CRO that has worked in degraders will design around it as a matter of course; if a prospective supplier cannot explain it, treat that as a sign they have not run a real degrader campaign.
How does BioBridgeX work for sourcing PROTAC CROs and CDMOs, and what does it cost?
BioBridgeX is free for buyers and acts as the neutral marketplace, so it has no reason to steer you toward a pricier lab. Suppliers pay a flat 2% platform fee. A degrader program usually spans several suppliers (linker and E3 chemistry, degradation and DMPK assays, then GMP CMC), and BioBridgeX lets you source and compare them, then contract directly with each chosen supplier in one place. Coverage spans every indication and modality, so the same setup works whether you are running an oncology degrader or one aimed at neurology or immunology.

Source PROTAC / Targeted Protein Degrader work with one contract

Compare transparent quotes from qualified PROTAC / Targeted Protein Degrader CRO and CDMO vendors, then contract once. Free for buyers.

Compare quotes